HomeInvestors HealthPTC's utreloxastat fails Phase 2 clinical study for ALS (NASDAQ:PTCT)

PTC’s utreloxastat fails Phase 2 clinical study for ALS (NASDAQ:PTCT)

November 27, 2024

ALS or Written on wooden blocks, Amyotrophic lateral sclerosis, a rare nervous system disease affecting the motor nerves in the cortex and brainstem and spinal cord, loss of muscle control — Andrzej Rostek

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet its primary and secondary efficacy endpoints.
The biotech company said the drug failed to demonstrate statistical significance in the slowing of disease

Previous article

Trading के लिए कितना पैसा होना चाहिए 🤔🤔। Trading। Option trading। #shorts

Next article

Rover’s Weekly Market Brief – 11/15/2024

Investors Health Image

latest articles

explore more

LEAVE A REPLY Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here